Why BGPT?
logo

Review Papers Claim by Claim

Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to start review



    Explore by Goal












     Quick Answer


    Concise verdict: This 2017 review (Nishida et al.) is a rigorous clinical–translational synthesis showing that dysbiosis (↓diversity, ↓butyrate-producers, ↑Proteobacteria/AIEC) is reproducibly associated with IBD, but causality in humans remains unproven and therapeutic translation (probiotics, FMT) is inconsistent; stronger longitudinal, mucosa-focused, functional (multi-omics) and standardized clinical trials are needed to move from association to mechanism and reliable therapy



     Long Answer


    Visual paper analysis — "Gut microbiota in the pathogenesis of inflammatory bowel disease" (Nishida et al., DOI:10.1007/s12328-017-0813-5)

    Primary claims & supporting evidence

    • Dysbiosis is reproducibly observed in IBD (reduced diversity; loss of Firmicutes/SCFA producers): documented across multiple cohorts and summarized in the review; loss of Faecalibacterium prausnitzii and butyrate-producers is highlighted as consistent
    • Pathobiont expansion (e.g., AIEC/E. coli) and mucosa-associated bacteria increase in CD: the review cites mucosal studies and AIEC prevalence estimates in active CD (≈38% in some cohorts)
    • Microbial metabolites (SCFAs) and functional changes are central mechanistic candidates: decreased SCFAs (butyrate) in IBD and links to epithelial energy/Treg induction are emphasized
    • Therapeutic manipulations (probiotics, VSL#3, E. coli Nissle, FMT) show mixed efficacy: stronger signal for UC (some RCTs) than CD; FMT effective for CDI but variable in UC trials; heterogeneity in protocols and donor effects likely limit reproducibility

    Critical appraisal — strengths & limitations

    Strengths:
    • Comprehensive literature synthesis in 2017 across mechanistic animal models and human clinical data (mucosa & feces).
    • Clear focus on plausible mechanistic links (SCFAs, mucosal colonization, AIEC) connecting ecology → metabolism → immunity.
    • Provides balanced discussion of therapeutic translational hurdles (FMT donor selection, trial heterogeneity).
    Limitations / blindspots highlighted:
    • Because it is a narrative review it cannot quantitatively weigh biases, publication bias, or heterogeneity across sequencing methods (16S vs shotgun).
    • By 2017, plausible causal human evidence (longitudinal, pre-disease sampling, interventional mechanistic RCTs) was sparse — review notes this uncertainty but cannot resolve it.
    • Underrepresentation of non-bacterial components (virome/mycobiome) except brief mentions; later work (post-2017) has emphasized virome contributions to FMT outcomes.

    What would improve the field (recommendations derived from review + modern critical appraisal)

    1. Standardize sampling (mucosa vs stool), sequencing (shotgun + strain-resolution), and metadata (diet, meds, antibiotics) across cohorts.
    2. Prioritize longitudinal cohorts with pre-disease or at-diagnosis samples and integrate host genotype to test host→microbe→disease directionality.
    3. Design mechanistic human RCTs with functional readouts (SCFA quantification, bile-acid profiling, mucosal transcriptomics) and rational donor selection for FMT.
    4. Expand to virome/mycobiome and multi-omics (metagenome, metatranscriptome, metabolome) to move from taxonomy to function.

    Primary citation used



    Feedback:    

    Updated: March 16, 2026

     BGPT Paper Review


    Study Novelty

    70%

    In 2017 the review consolidated emerging high-throughput sequencing and gnotobiotic mechanistic literature into a clinical-translational narrative; not wholly novel conceptually (microbiota–IBD link was known) but novel in its synthesis and translational emphasis.


    Scientific Quality

    80%

    Well-referenced, balanced narrative synthesis; transparent citation of human cohorts and animal models. Limitations: narrative (not systematic) design, inherent reliance on heterogeneous primary studies and absence of meta-analytic weighting; funding declarations present (multiple Japanese agencies) and authors report no COI.


    Study Generality

    80%

    Covers broad IBD biology (UC and CD), multiple taxa, metabolites, host genetics interplay, and therapeutics — findings generalize across many patient contexts though constrained by cohort heterogeneity.


    Study Usefulness

    80%

    Useful for clinicians/researchers as a roadmap to microbiota mechanisms and therapeutic avenues circa 2017; highlights where evidence was lacking and where trials are needed.


    Study Reproducibility

    60%

    As a narrative review, reproducibility depends on primary data. The review cites many studies but does not supply meta-analytic code or raw data; reproducibility of claims requires access to original datasets and standardized reanalysis.


    Explanatory Depth

    70%

    Provides mechanistic links (SCFA→epithelium/Treg, AIEC adherence/invasion) and integrates animal model causation; depth limited by available human causal data at the time.


    🎁 Authors: Collect 301 Free Science Tokens (≈ $30.1 USD)

    Claim My Author Tokens

    Use for 75 days of free BGPT access (4 tokens = 1 day) or trade/sell (≈ $30.1 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    Preparing reproducible multi-omics reanalysis pipeline: pulling available 16S/shotgun/metadata from cited cohorts, harmonizing taxonomy, computing differential abundance and SCFA-pathway functional profiles, and producing meta-analytic effect sizes for taxa linked to IBD.



     Hypothesis Graveyard


    Single-pathogen causation (e.g., MAP alone causes CD) — evidence is inconsistent and fails to explain heterogenous clinical phenotypes or global incidence patterns.


    Probiotics alone (single strain) curing IBD — RCTs (especially in CD) and mechanistic work show single-strain approaches are insufficient for complex dysbiosis and mucosal colonization deficits.

     Science Art


    Paper Review: Gut microbiota in the pathogenesis of inflammatory bowel disease Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending